Sana D. Karam

Sep 10, 2024 | biorxiv.org | Sana D. Karam |Jacob Gadwa |Justin Yu |Miles Piper

AbstractBackground: Treatment with immunotherapy can elicit varying responses across cancer types, and the mechanistic underpinnings that contribute to response vs. progression remain poorly understood. However, to date there are few preclinical models that accurately represent these disparate disease scenarios.

May 29, 2024 | nature.com | Sana D. Karam |Robin Dowell

AbstractDynamic regulation of gene expression is fundamental for cellular adaptation to exogenous stressors. P-TEFb-mediated pause-release of RNA polymerase II (Pol II) is a conserved regulatory mechanism for synchronous transcriptional induction in response to heat shock, but this pro-survival role has not been examined in the applied context of cancer therapy.

Dec 13, 2023 | bmj.com | Marco Del Chiaro |Toshitaka Sugawara |Sana D. Karam |Wells Messersmith

Clinical Review State of the Art Review BMJ 2023; 383 doi: https://doi.org/10.1136/bmj-2022-073995 Cite this as: BMJ 2023;383:e073995 Marco Del Chiaro, professor, division chief, clinical director1 2, Toshitaka Sugawara, assistant clinical professor1 3, Sana D Karam, professor2 4, Wells A Messersmith, professor, division head,, associate director2 5 1Division of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA 2University of Colorado Cancer...

Mar 12, 2023 | redjournal.org | Marsha Reyngold |Sana D. Karam |Carla Hajj |Abraham J. Wu

Purpose The optimal dose and fractionation of stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer (LAPC) have not been defined. Single-fraction SBRT was associated with more gastrointestinal toxicity, so 5-fraction regimens have become more commonly employed. We aimed to determine the safety and maximally tolerated dose of 3-fraction SBRT for LAPC.